Drug Trial Radar · NCT07005557
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,244
Planned (sponsor's estimate)
Start
Jun 15, 2025
Primary completion
May 15, 2030
Study completion May 15, 2035
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged \>65 years) with lymph node-positive, HR+/HER2- breast cancer.
Conditions
- Breast Cancer
- Adjuvant Therapy
Interventions
ChemotherapyDrug
Chemotherapy options at physician's discretion: TC, EC-T(wP), or capecitabine.
CDK4/6 InhibitorDrug
All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)
Endocrine therapyDrug
Endocrine therapy (letrozole/anastrozole/exemestane)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-years Invasive disease free survivalTime frame: 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.